IBIO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q3

FY2026Q4

25.00K

-87.5%

-0.093

-80.56%

-0.057

-88.43%

-0.067

-79.17%

Estimates Revision

The market is revising Upward the revenue expectations for iBio, Inc. (IBIO) for FY2026, with the revenue forecasts being adjusted by 80% over the past three months. During the same period, the stock price has changed by 171.27%.

Revenue Estimates for FY2026

Revise Upward

+80%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+9.62%

In Past 3 Month

Stock Price

Go Up

+171.27%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast IBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBIO is 4.67 USD with a low forecast of 2.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

2.00

Averages

4.67

High

6.00

Current: 0.000

Low

2.00

Averages

4.67

High

6.00

LifeSci Capital

initiated

2025-12-18

Reason

LifeSci Capital

Price Target

2025-12-18

initiated

Reason

LifeSci Capital initiated coverage of iBio with an Outperform rating and $5 price target.

Oppenheimer

Jay Olson

Outperform

maintain

$5 -> $6

2025-10-30

Reason

Oppenheimer

Jay Olson

Price Target

$5 -> $6

2025-10-30

maintain

Outperform

Reason

Oppenheimer analyst Jay Olson raised the firm's price target on iBio to $6 from $5 and keeps an Outperform rating on the shares. The firm notes shares were up 8% vs. flat XBI, basking in well-deserved attention for IBIO-610 following updates from WVE's INHBE-targeting siRNA WVE-007. In its Phase 1 INLIGHT trial, WVE-007 elicited up to about 85% activin E reduction, surpassing the preclinical 70% activin E reduction threshold for potential 6-month weight loss comparable to semaglutide.

Oppenheimer

Outperform

maintain

$5 -> $6

2025-10-29

Reason

Oppenheimer

Price Target

$5 -> $6

2025-10-29

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on iBio (IBIO) to $6 from $5 and keeps an Outperform rating on the shares, calling attention for IBIO-610 following updates from Wave Life Sciences' (WVE) WVE-007 "well-deserved." Wave's initial Phase 1 INLIGHT efficacy and safety readout this quarter could provide mechanistic validation for iBio's '601 and drive additional upside, the analyst tells investors.

Oppenheimer

Outperform

initiated

2025-10-20

Reason

Oppenheimer

Price Target

2025-10-20

initiated

Outperform

Reason

Oppenheimer initiated coverage of iBio with an Outperform rating and $5 price target, citing "optimism" for lead asset IBIO-610 to address key challenges in treating the growing obesity market. Preclinical data validate the potential of '610 to drive both fat loss and lean mass preservation, supporting "a highly differentiated and complementary profile," says the analyst, who views the drug as "an under-the-radar" next-generations approach that "could command strategic interest."

Leerink

Roanna Ruiz

Outperform

initiated

2025-10-17

Reason

Leerink

Roanna Ruiz

Price Target

2025-10-17

initiated

Outperform

Reason

Leerink analyst Roanna Ruiz initiated coverage of iBio with an Outperform rating and $2 price target. The firm argues that lead obesity asset IBIO-610 represents a preclinically validated, first-in-class antibody opportunity that could address the safety and durability limitations of RNA-based competitors. Following the recent $50M public offering, iBio should maintain liquidity through all pre-IND and IND catalysts, with Series G and H warrants providing up to an additional $50M in contingent capital tied to IND milestones, Leerink adds. This structure should support a self-funding runway through the second half of 2026, aligning with the expected IND filings for IBIO-610 and IBIO-600 by year-end 2026. Further, the firm believes iBio's proprietary AI/ML-driven antibody discovery and engineering platform should provide enhanced scalability and speed to identify and optimize novel biologics.

Valuation Metrics

The current forward P/E ratio for iBio Inc (IBIO.A) is -6.38, compared to its 5-year average forward P/E of -4.08. For a more detailed relative valuation and DCF analysis to assess iBio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.08

Current PE

-6.38

Overvalued PE

3.24

Undervalued PE

-11.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

92.45

Current PS

605.66

Overvalued PS

215.85

Undervalued PS

-30.95

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IBIO News & Events

Events Timeline

No data

News

2.0

2025-12-09NASDAQ.COM

After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences

9.0

2025-10-30Newsfilter

iBio Reveals Promising Non-Human Primate Data for IBIO-610, an Activin E Antibody with Significant Potential for Targeted Weight Loss and Maintenance

1.0

2025-10-23Newsfilter

iBio to Attend the 2nd Annual Healthcare Innovation Conference Hosted by Guggenheim

People Also Watch

Frequently Asked Questions

What is iBio Inc (IBIO) stock price today?

The current price of IBIO is 2.35 USD — it has increased 8.29 % in the last trading day.

What is iBio Inc (IBIO)'s business?

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

What is the price predicton of IBIO Stock?

What is iBio Inc (IBIO)'s revenue for the last quarter?

iBio Inc revenue for the last quarter amounts to 100.00K USD, decreased % YoY.

What is iBio Inc (IBIO)'s earnings per share (EPS) for the last quarter?

iBio Inc. EPS for the last quarter amounts to -0.11 USD, decreased -76.09 % YoY.

What changes have occurred in the market's expectations for iBio Inc (IBIO)'s fundamentals?

How many employees does iBio Inc (IBIO). have?

iBio Inc (IBIO) has 20 emplpoyees as of January 09 2026.

What is iBio Inc (IBIO) market cap?

Today IBIO has the market capitalization of 52.85M USD.